Revenues

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

REVENUES

Disaggregation of Revenues

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):



	Three Months Ended March 31, 2020								Three Months Ended March 31, 2019
	U.S.		Europe		Other Locations		Total		U.S.		Europe		Other Locations		Total
Product sales:
Atripla	$	81	$	7	$	7	$	95	$	133	$	16	$	22	$	171
Biktarvy	1,412		181		100		1,693		739		48		6		793
Complera/Eviplera	24		47		5		76		44		62		9		115
Descovy	363		61		34		458		233		68		41		342
Genvoya	612		151		61		824		728		193		94		1,015
Odefsey	269		127		13		409		282		106		9		397
Stribild	34		17		2		53		67		18		11		96
Truvada	383		8		15		406		551		33		22		606
Other HIV⁽¹⁾	3		2		3		8		11		1		5		17
Revenue share – Symtuza⁽²⁾	72		38		2		112		42		24		—		66
AmBisome	18		59		42		119		8		57		28		93
Ledipasvir/Sofosbuvir⁽³⁾	53		11		48		112		117		27		81		225
Letairis	83		—		—		83		197		—		—		197
Ranexa	8		—		—		8		155		—		—		155
Sofosbuvir/Velpatasvir⁽⁴⁾	311		122		131		564		230		154		107		491
Vemlidy	73		7		56		136		65		4		32		101
Viread	4		11		25		40		12		14		46		72
Vosevi	33		11		4		48		45		16		2		63
Yescarta	103		37		—		140		90		6		—		96
Zydelig	8		12		—		20		11		15		1		27
Other⁽⁵⁾	42		18		3		63		36		20		6		62
Total product sales	3,989		927		551		5,467		3,796		882		522		5,200
Royalty, contract and other revenues	17		48		16		81		22		56		3		81
Total revenues	$	4,006	$	975	$	567	$	5,548	$	3,818	$	938	$	525	$	5,281



____________________
Notes:
(1)	Includes Emtriva and Tybost
(2)	Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC
(3)	Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4)	Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5)	Includes Cayston, Hepsera and Sovaldi.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):



	Three Months Ended
	March 31,
	2020		2019
AmerisourceBergen Corp.	22	%	21	%
Cardinal Health, Inc.	22	%	20	%
McKesson Corp.	21	%	20	%

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $188 million and $155 million for the three months ended March 31, 2020 and 2019, respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $38 million and $107 million increase in revenues for the three months ended March 31, 2020 and 2019, respectively.

Contract Balances

Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $140 million and $144 million as of March 31, 2020 and December 31, 2019, respectively. Contract liabilities were not material as of March 31, 2020 and December 31, 2019.